Several key developments have emerged within Teva Pharmaceutical Industries, influencing investor sentiment. Barclays repeatedly reiterates its stock rating on the company amid market volatility. This point mixed with the strong share price rally of 75% & 102% over the past year has led to questions from analysts about whether it is a good buy in the current scenario. The valuation of the company seems attractive with its branded drugs crossing $1b in quarterly revenue. Austedo's positive outlook has played an important role in increasing Teva's stock price target for Piper Sandler. At the same time, Goldman Sachs sees the company achieving double-digit earnings growth through 2026.
Institutional investors, owing a large part of TEVA, have considerable investment stakes- with Farallon Capital Management and Brevan Howard Capital Management making substantial investments. However, some insiders have been selling shares, including Mark Sabag (TEVA officer) and Richard Daniell (EVP). Despite these sales, the company continues to impress with strong institutional ownership and return performance.
Teva Pharmaceutical Stocks News Analytics from Thu, 21 Aug 2025 07:00:00 GMT to Thu, 19 Mar 2026 20:30:00 GMT - Rating 5 - Innovation 7 - Information 8 - Rumor -2
